Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Procainamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.59 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.59 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.94 |
| ▸ | LMNA | P02545 | 2/20 | 0.94 |
| ▸ | TSHR | P16473 | 2/20 | 0.94 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.94 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.94 |
| ▸ | ACHE | P22303 | 1/20 | 0.94 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.94 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.94 |
| ▸ | BLM | P54132 | 3/20 | 0.91 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.91 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Procainamide SCHEMBL9618624 | 0.97 | BLM (0.97) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL15914 | 0.97 | ALDH1A1 (1.00) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL9614531 | 0.95 | BLM (1.00) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL40758 | 0.95 | BLM (1.00) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL28944214 | 0.95 | ALDH1A1 (0.97) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL23270847 | 0.94 | BLM (0.97) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL5443536 | 0.94 | BLM (0.97) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL10717171 | 0.94 | BLM (0.97) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL9437783 | 0.94 | BLM (0.97) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL9592794 | 0.94 | BLM (0.97) | ALDH1A1LMNATSHRSLC22A2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20230174641-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | H LUNDBECK AS (DK) | 2023-06-08 | — | — | US | claimed |
| EP-4066850-A2 | PEPTIDES AND METHODS OF TREATING DYSTROPHY-RELATED DISORDERS USING THE SAME | Bioincept LLC (US) | 2022-10-05 | — | — | EP | claimed |
| EP-3835319-A1 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | Alder Biopharmaceuticals, Inc. (US) | 2021-06-16 | — | — | EP | claimed |
| EP-3753950-A2 | ANTI-PCSK9 ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2020-12-23 | — | — | EP | claimed |
| US-20200317772-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | ALDERBIO HOLDINGS LLC (US) | 2020-10-08 | — | — | US | claimed |
| US-20190085073-A1 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. LUNDBECK A/S (DK) | 2019-03-21 | — | — | US | claimed |
| US-20170334987-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | H. LUNDBECK A/S (DK) | 2017-11-23 | — | — | US | claimed |
| EP-3233916-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | Alder Biopharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | claimed |
| CN-1188440-C | Functionalized polymeric media for separation of analytes | MALLINCKRODTBECK INC (US) | 2005-02-09 | — | — | CN | claimed |
| CN-1469737-A | Medicinal composition capable of rapidly disintegrating in oral cavity and preparation method thereof | ��һ��������ҩ��ʽ���� | 2004-01-21 | — | — | CN | claimed |
| CN-1449416-A | Functionalized polymeric media for separation of analytes | MALLINCKRODT INC (US) | 2003-10-15 | — | — | CN | claimed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | claimed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| CN-1072965-C | Improved topical delivery of drugs | PROCTER & GAMBLE (US) | 2001-10-17 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| CN-1183044-A | preparation composition containing sucralfate | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1998-05-27 | — | — | CN | claimed |
| CN-1163612-A | Preparation of immunogens and other conjugates of drugs | DADE CHEMISTRY SYSTEMS INC (US) | 1997-10-29 | — | — | CN | claimed |
| CN-1091317-A | Improve the part input of medicine | PROCTER & GAMBLE (US) | 1994-08-31 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190085073-A1 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | CRH, MC2R, CRHR1 | SCN1A 2484/4885SCN2A 3346/4885SCN3A 2761/4885 |
| US-20230174641-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | CRH, MC2R, GIPR | SCN1A 2405/4885SCN2A 3129/4885SCN3A 2255/4885 |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | APOB, MMAB, CBS | SCN1A 3962/4885SCN2A 3983/4885SCN3A 3723/4885 |
| US-20170334987-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | CRH, MC2R, GIPR | SCN1A 2405/4885SCN2A 3129/4885SCN3A 2255/4885 |
| US-20200317772-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | CRH, MC2R, GIPR | SCN1A 2405/4885SCN2A 3129/4885SCN3A 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.